30095-50-2

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 2-bromo-1-(3-chloro-4-methoxyphenyl)is used as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its unique structural features allow for the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
Ethanone, 2-bromo-1-(3-chloro-4-methoxyphenyl)is used as a building block in the synthesis of agrochemical compounds, such as pesticides and herbicides. Its versatility in chemical reactions enables the creation of novel agrochemicals with enhanced performance and selectivity.
Used in Medicinal Chemistry Research:
Ethanone, 2-bromo-1-(3-chloro-4-methoxyphenyl)is utilized as a valuable research tool in medicinal chemistry. Its structural features make it a promising candidate for the development of new drug candidates, as well as for studying the structure-activity relationships of biologically active compounds.
Used in Synthesis of Biologically Active Compounds:
Ethanone, 2-bromo-1-(3-chloro-4-methoxyphenyl)serves as a versatile starting material for the synthesis of a wide range of biologically active compounds. Its reactivity and functional group compatibility make it suitable for various synthetic routes, leading to the production of compounds with potential applications in medicine, agriculture, and other fields.

Upstream product

• 37612-52-5 4-acetyl-2-chloroanisole 
• 766-51-8 2-Chloroanisole 
• 598-21-0 2-Bromoacetyl bromide 
• 173776-64-2 3-Chloro-4,N-dimethoxy-N-methyl-benzamide 
• 37908-96-6 3-chloro-4-methoxy benzoic acid 

Downstream Products

• 107519-58-4 benzofuran-2-yl-(3-chloro-4-methoxy-phenyl)-ketone 
• 101081-18-9 (5-bromo-benzofuran-2-yl)-(3-chloro-4-methoxy-phenyl)-ketone 
• 173776-66-4 2-[2-(3-Chloro-4-methoxy-phenyl)-2-oxo-ethyl]-2-[2-(4-methanesulfonyl-phenyl)-2-oxo-ethyl]-malonic acid dimethyl ester 
• 892405-42-4 1-(3-chloro-4-methoxy-phenyl)-2-{[3-(3-hydroxy-propoxy)-benzyl]-methyl-amino}-ethanone 
• 102440-92-6 (5-bromo-benzofuran-2-yl)-(3-bromo-5-chloro-4-hydroxy-phenyl)-ketone 
• 100914-04-3 (5-bromo-benzofuran-2-yl)-(3-chloro-4-hydroxy-phenyl)-ketone 
• 55877-28-6 benzofuran-2-yl-(3-chloro-4-hydroxy-phenyl)-ketone 
• 173776-70-0 C₃₅H₃₅ClO₉S₃ 

Relevant academic research and scientific papers

Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer

The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is one of the more recently identified mammalian sources of H2S. A recent study identified several novel 3-MST inhibitors with micromolar potency. Among those, (2-[(4-hydroxy-6-methylpyrimidin-2-yl)sulfanyl]-1-(naphthalen-1-yl)ethan-1-one) or HMPSNE was found to be the most potent and selective. We now took the central core of this compound and modified the pyrimidone and the arylketone sides independently. A 63-compound library was synthesized; compounds were tested for H2S generation from recombinant 3-MST in vitro. Active compounds were subsequently tested to elucidate their potency and selectivity. Computer modeling studies have delineated some of the key structural features necessary for binding to the 3-MST's active site. Six novel 3-MST inhibitors were tested in cell-based assays: they exerted inhibitory effects in murine MC38 and CT26 colon cancer cell proliferation; the antiproliferative effect of the compound with the highest potency and best cell-based activity (1b) was also confirmed on the growth of MC38 tumors in mice.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT

Provided are a compound as represented in formula (I), a pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and uses thereof. The compound as represented in formula (I) and the pharmaceutically acceptable salts thereof are used in the preparation of medicines for the treatment or prevention of hyperuricemia or gout by means of uric acid excretion.

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis

Abstract The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gating) of CFTR protein. Other mutations, like G551D, only cause a gating defect. Processing and gating defects can be targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide indications about the chemical groups that are beneficial or detrimental for rescue activity. The new compounds were tested as correctors and potentiators in CFBE41o-expressing F508del-CFTR using a functional assay. A dual active compound, AAT-4a, characterized by improved efficacy and marked synergy when combined with the corrector VX-809 has been identified. Moreover, by computational methods, a possible binding site for AATs in nucleotide binding domain NBD1 has been detected. These results will direct the synthesis of new analogues with possibly improved activity.

Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure-activity relationships

A novel series of 5,6-diarylspiro[2.4]hept-5-enes was shown to provide highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. A study of structure-activity relationships in this series suggests that 3,4- disubstituted phenyl analogs are generally more selective than 4-substituted phenyl analogs and that replacement of the methyl sulfone group on the 6- phenyl ring with a sulfonamide moiety results in compounds with superior in vivo pharmacological properties, although with lower COX-2 selectivity. Several compounds have been shown to possess promising pharmacological properties in adjuvant-induced arthritis and edema analgesia models. The absence of gastrointestinal (GI) toxicity at 200 mpk of several selected compounds in rats and mice corresponds well with the weak potency for inhibition of COX-1 observed in the enzyme assay. Methyl sulfone 55 and sulfonamide 24 were shown to have superior in vivo pharmacological profiles, low GI toxicity, and good oral bioavailability and duration of action.

Halogenated 4'-methoxyacetophenones as microbicides and preservatives

Halogenated 4'-methoxyacetophenones of formula I: STR1 wherein X is a halogen; Y is a halogen; and n is 1 or 2 as microbicides for inhibiting the growth of microorganisms in aqueous systems and on surfaces, as well as for inhibiting slime formation in aqueous systems and biocidal compositions containing effective amounts of the halogenated 4'-methoxyacetophenones.